- Home
- SWIM vs CSTL Comparison
SWIM vs CSTL Comparison
Compare SWIM & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SWIM
- CSTL
- Stock Information
- Founded
- SWIM 1956
- CSTL 2007
- Country
- SWIM United States
- CSTL United States
- Employees
- SWIM N/A
- CSTL N/A
- Industry
- SWIM Plastic Products
- CSTL Medical Specialities
- Sector
- SWIM Industrials
- CSTL Health Care
- Exchange
- SWIM Nasdaq
- CSTL Nasdaq
- Market Cap
- SWIM 678.4M
- CSTL 561.9M
- IPO Year
- SWIM 2021
- CSTL 2019
- Fundamental
- Price
- SWIM $6.92
- CSTL $16.45
- Analyst Decision
- SWIM Hold
- CSTL Strong Buy
- Analyst Count
- SWIM 4
- CSTL 6
- Target Price
- SWIM $6.70
- CSTL $37.67
- AVG Volume (30 Days)
- SWIM 570.3K
- CSTL 425.9K
- Earning Date
- SWIM 08-05-2025
- CSTL 08-04-2025
- Dividend Yield
- SWIM N/A
- CSTL N/A
- EPS Growth
- SWIM N/A
- CSTL N/A
- EPS
- SWIM N/A
- CSTL N/A
- Revenue
- SWIM $509,311,000.00
- CSTL $347,083,000.00
- Revenue This Year
- SWIM $9.24
- CSTL N/A
- Revenue Next Year
- SWIM $5.86
- CSTL $1.36
- P/E Ratio
- SWIM N/A
- CSTL N/A
- Revenue Growth
- SWIM N/A
- CSTL 38.43
- 52 Week Low
- SWIM $2.91
- CSTL $15.45
- 52 Week High
- SWIM $8.41
- CSTL $35.84
- Technical
- Relative Strength Index (RSI)
- SWIM 59.22
- CSTL 33.31
- Support Level
- SWIM $5.95
- CSTL $16.16
- Resistance Level
- SWIM $7.08
- CSTL $17.31
- Average True Range (ATR)
- SWIM 0.28
- CSTL 0.82
- MACD
- SWIM 0.02
- CSTL -0.41
- Stochastic Oscillator
- SWIM 85.84
- CSTL 6.50
About SWIM Latham Group Inc.
Latham Group Inc is a designer, manufacturer, and marketer of in-ground residential swimming pools, liners, and covers in North America, Australia, and New Zealand. It derives a majority of its revenue from the United States.
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.